NCT01875874 is a Phase 2 clinical trial of ELAD in Acute Liver Failure, sponsored by Vital Therapies, Inc..

Who is sponsoring NCT01875874?

NCT01875874 is sponsored by Vital Therapies, Inc..

What drugs are being tested in NCT01875874?

Interventions in NCT01875874: ELAD.

What condition does NCT01875874 study?

NCT01875874 studies Acute Liver Failure, Fulminant Hepatic Failure, Primary Graft Non-Function, Surgically-Induced Liver Failure.

Is NCT01875874 still recruiting?

NCT01875874 is currently terminated. Last updated 22 January 2019.

Are results published for NCT01875874?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-01-22 · How we verify

NCT01875874

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Open-Label, Multicenter, Historically-Controlled Study to Assess Safety and Efficacy of ELAD in Subjects With Acute Liver Failure (ALF)

Terminated Phase 2 Results posted Last updated 22 January 2019

What this trial tests

Phase 2 trial testing ELAD in Acute Liver Failure in 8 participants. Terminated before completion.

Timeline

1 October 2014

Primary endpoint
1 September 2015

1 September 2018

Quick facts

Lead sponsor	Vital Therapies, Inc.
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	8
Start date	1 October 2014
Primary completion	1 September 2015
Estimated completion	1 September 2018
Sites	18 locations across United States

Drugs / interventions tested

ELAD — full drug profile →

Conditions studied

Acute Liver Failure — all drugs for Acute Liver Failure →
Fulminant Hepatic Failure — all drugs for Fulminant Hepatic Failure →
Primary Graft Non-Function — all drugs for Primary Graft Non-Function →
Surgically-Induced Liver Failure — all drugs for Surgically-Induced Liver Failure →

Sponsor

Vital Therapies, Inc. — full company profile →

Who can join

18 and older, any sex, with Acute Liver Failure or Fulminant Hepatic Failure. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Overall Survival (OS) of ALF Subjects
Time frame: Study Day 1 through Study Day 28

Sponsor's own description

This phase 2 study is developed to evaluate the effect of ELAD on overall survival (OS) in subjects with acute liver failure (ALF) compared to matched historical controls.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Acute Liver Failure

Currently open trials in the same condition.

NCT06831643 — Standard Volume vs. High Volume Plasma Exchange in Pediatric Acute Liver Failure · NA · recruiting
NCT06872372 — Role of N-Acetylcysteine in Non-Acetaminophen-Induced Acute Liver Failure · NA · active not recruiting
NCT07329036 — ALSS - DPMAS and Therapeutic Plasma Exchange (TPE), Its Effect on Primary Coagulation, Inflammation and the Function of · NA · recruiting
NCT05689645 — F573 for Injection for the Treatment of Liver Injury/Failure · Phase 2 · recruiting
NCT05413083 — Evaluation of Cardiac Function in Acutely Decompensated Cirrhosis · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01875874 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vital Therapies, Inc.
Last refreshed: 22 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01875874.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing